PRECISIONGATE Trademark

Trademark Overview

On Thursday, January 21, 2021, a trademark application was filed for PRECISIONGATE with the United States Patent and Trademark Office. The USPTO has given the PRECISIONGATE trademark a serial number of 90479940. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 18, 2024. This trademark is owned by Revitope Oncology, Inc.. The PRECISIONGATE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Development of pharmaceutical preparations for the treatment of cancer; development of platform technology, namely, immunotherapy platforms for manufacturing cancer therapeutics; scientific research services, namely, antibody engineering for analytical and clinical purposes

General Information

Serial Number90479940
Word MarkPRECISIONGATE
Filing DateThursday, January 21, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 17, 2021

Trademark Statements

Pseudo MarkPRECISION GATE
Goods and ServicesDevelopment of pharmaceutical preparations for the treatment of cancer; development of platform technology, namely, immunotherapy platforms for manufacturing cancer therapeutics; scientific research services, namely, antibody engineering for analytical and clinical purposes

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, April 22, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRevitope Oncology, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameRevitope Oncology, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Monday, January 25, 2021NEW APPLICATION ENTERED
Thursday, April 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, June 20, 2021ASSIGNED TO EXAMINER
Sunday, July 11, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 28, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 17, 2021PUBLISHED FOR OPPOSITION
Tuesday, August 17, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 12, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 29, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, March 29, 2022SOU EXTENSION 1 FILED
Tuesday, March 29, 2022SOU EXTENSION 1 GRANTED
Thursday, March 31, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 12, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, October 12, 2022SOU EXTENSION 2 FILED
Wednesday, October 12, 2022SOU EXTENSION 2 GRANTED
Friday, October 14, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, April 11, 2023SOU EXTENSION 3 FILED
Tuesday, April 11, 2023SOU EXTENSION 3 GRANTED
Thursday, April 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 10, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, October 10, 2023SOU EXTENSION 4 FILED
Tuesday, October 10, 2023SOU EXTENSION 4 GRANTED
Thursday, October 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 12, 2024SOU TEAS EXTENSION RECEIVED
Friday, April 12, 2024SOU EXTENSION 5 GRANTED
Friday, April 12, 2024SOU EXTENSION 5 FILED
Saturday, April 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 18, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, November 18, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

precisiongate namely cancer development research antibody services engineering purposes clinical analytical